Compugen Reports First Quarter 2020 Results

Go back to Compugen Reports First Quarter 2020 Results

Compugen (CGEN) Reports In-Line Q1 EPS

May 6, 2020 7:20 AM EDT

Compugen (NASDAQ: CGEN) reported Q1 EPS of ($0.10), in-line with the analyst estimate of ($0.10).

"We have entered 2020 well positioned and with significant momentum to advance our clinical programs that address novel, internally-discovered, drug targets for cancer immunotherapy," said Anat Cohen-Dayag, Ph.D., President and CEO of Compugen. "On the clinical front, we recently presented at AACR updated data from our ongoing Phase 1 dose escalation study of COM701 as a monotherapy and in combination with Opdivo®. These encouraging data, which include... More